Eli Lilly (NYSE: LLY) is entering 2026 with explosive revenue growth, strong momentum in its powerful obesity drug, and multiple Phase 3 catalysts. With guidance pointing toward $83 billion in revenue and analysts targeting major upside, this healthcare giant could still have significant room to run.
Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.
